Translational research in nanomedicine: Nanomedicine is expected to become the next big thing in the pharmaceutical sector. The healthcare nanotechnology market is estimated to grow at a CAGR of 12% from 2014 to 2020 (forecast period). It should be valued around USD 195 billion by 2020. However, in order to accelerate the development of nanomedicine there are some key points where the scientific community is focusing, i.e. regulatory aspects, GMP manufacturing, standardization and characterization. This round table will bring together some experts in the field and will discuss on:
• Technology transfer from a point of view of technology developers generating their own technology on nanodelivery systems, and developing GMP processes for the production of small batches.
• Characterization of nanopharmaceuticals from basic research to clinical development (validation, standardization of methods…).
• Regulatory challenges for the development of innovative medicines.
• Industrial point of view, where we will have some examples highly innovative biotechnological companies in the field.

Chairman: Dr. Ana Benito, Senior Researcher in IK4-CIDETEC.

• Covadonga Pañeda: R&D Manager at SYLENTIS, Madrid, Spain.
• Iraida Loinaz: Health Business Development Manager, IK4-CIDETEC, Donostia-San Sebastián, Spain.
• SIMON BACONNIER, Clinical Alliance Manager at CLINATEC, Grenoble, France.
• Eusebio Gainza, R&D Manager BIOPRAXIS RESEARCH, Vitoria-Gasteiz, Spain.
• Justin Barry, Managing Director at Midatech Pharma, Bilbo-Bilbao, Spain.

07 June, 2017 · Overview

NANOPILOT project present in the 37th Symposium of AEFI (Spanish Association of Pharmaceutical Industry).

NANOPILOT project present in the 37th Symposium of AEFI (Spanish Association of Pharmaceutical Industry) that is held in Barcelona (Spain) 7th-8th of June 2017. Title of the presentation: “PROYECTO NANOPILOT: Diseño y puesta en marcha de una Planta Piloto de producción de nano fármacos en un entorno GMP”. Read more